Grifols lifts 2025 targets but fibrinogen delay and forex drag weigh on outlook
Grifols posted better-than-expected Q3 results and raised its 2025 targets at February FX rates, supported by strong immunoglobulin demand and healthier free cash flow. Yet FX headwinds and a potential Regulatory approval delay for fibrinogen in the United States tempered market enthusiasm.
Published on 11/06/2025
at 10:01 am GMT - Modified on 11/06/2025
at 09:30 am GMT
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:
- products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (2.9%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
This Alphavalue article, the European leader in independent research, is only available to subscribers .
